zalcitabine has been researched along with pyrimethamine in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Childress, JF; DeMets, DL; Ellenberg, SS; Fleming, TR; Foulkes, M; Mayer, KH; O'Fallon, J; Pollard, RB; Rahal, JJ; Whitley, RJ | 1 |
5 other study(ies) available for zalcitabine and pyrimethamine
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
Topics: Advisory Committees; Anti-Infective Agents; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Confidentiality; Conflict of Interest; Didanosine; Drug Evaluation; Federal Government; HIV Infections; Humans; National Institutes of Health (U.S.); Organizational Objectives; Professional Staff Committees; Pyrimethamine; Reverse Transcriptase Inhibitors; Risk Assessment; Toxoplasmosis, Cerebral; Treatment Outcome; United States; Zalcitabine; Zidovudine | 1995 |